BeyondSpring Files 2022 Annual Report on Form 20-F
BeyondSpring Inc. (Nasdaq: BYSI), a clinical-stage biopharmaceutical company, announced the filing of its annual report on Form 20-F for the fiscal year ending December 31, 2022, with the SEC on April 18, 2023. This report includes audited consolidated financial statements accessible via the SEC and BeyondSpring's website. The company emphasizes its commitment to providing free hard copies of its report to shareholders upon request.
BeyondSpring focuses on developing innovative therapies for patients with high unmet medical needs, leveraging its unique drug discovery platform. Its lead asset, Plinabulin, is under study for various cancer indications, with promising Phase 3 results in combination with chemotherapy to prevent neutropenia and improve survival rates in non-small cell lung cancer. The company also has multiple preclinical immuno-oncology assets.
- Filing of the annual report may enhance transparency and investor confidence.
- Positive Phase 3 data for Plinabulin, demonstrating potential in cancer treatment.
- Partnership with Eli Lilly for drug development through SEED Therapeutics.
- Diverse pipeline including multiple preclinical assets in immuno-oncology.
- Risks associated with going concern and financing future operations.
- Potential delays or denials in regulatory approvals for product candidates.
- Increased competition in the biopharmaceutical market.
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical-stage global biopharmaceutical company focused on using its novel technology platform for drug discovery and development of innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2022 with the U.S. Securities and Exchange Commission (“SEC”) on April 18, 2023. The annual report on Form 20-F, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at www.sec.gov and on the Company’s website at www.beyondspringpharma.com under “Financials & Filings” in the Investors section.
The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to Investor Relations, BeyondSpring Inc., 28 Liberty Street, 39th Floor, New York, NY 10005 USA.
About BeyondSpring
Headquartered in New York City, BeyondSpring is a clinical-stage global biopharmaceutical company focused on using its novel technology platform for drug discovery and development of innovative therapies to improve clinical outcomes for patients with high unmet medical needs. Its subsidiary SEED Therapeutics is leveraging a proprietary targeted protein degradation drug discovery platform with an initial R&D collaboration with Eli Lilly. Its first-in-class lead asset, Plinabulin, is being developed as a potential “pipeline in a drug” in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). The Plinabulin and G-CSF combination for the prevention of CIN has demonstrated positive Phase 3 data in the PROTECTIVE-2 study. In the DUBLIN-3 study, a global, randomized, active controlled Phase 3 study, the Plinabulin and docetaxel combination met the primary endpoint of extending overall survival compared to docetaxel alone in 2nd/3rd line non-small cell lung cancer (NSCLC) (EGFR wild type). Additionally, Plinabulin is being broadly studied in combination with various immuno-oncology regimens that could boost the efficacy of PD-1/PD-L1 antibodies in seven different cancers. Lastly, BeyondSpring’s pipeline includes three preclinical immuno-oncology assets and a subsidiary.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements that are not historical facts. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, our ability to continue as a going concern, difficulties raising the anticipated amount needed to finance the Company’s future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet the Company’s expectations regarding the potential safety, the ultimate efficacy or clinical utility of the Company’s product candidates, increased competition in the market, the Company’s ability to meet Nasdaq's continued listing requirements, and other risks described in BeyondSpring’s most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Investor Contact:
IR@beyondspringpharma.com
Media Contact:
PR@beyondspringpharma.com
FAQ
What are the key highlights from BeyondSpring's Form 20-F filed on April 18, 2023?
How did Plinabulin perform in clinical trials according to the recent press release?
What is the significance of the partnership with Eli Lilly for BeyondSpring?
What risks did BeyondSpring mention in their annual report?
